| Catalog No. | 
			TD-VK617016 | 
		
		
			| Species reactivity | 
			Human immunodeficiency virus 1 (HIV-1) | 
		
		
			| Applications | 
			Research Grade Biosimilar | 
		
		
			| Host species | 
			Humanized | 
		
		
			| Isotype | 
			IgG1, kappa | 
		
		
			| Expression system | 
			Mammalian Cells | 
		
		
			| Clonality | 
			Monoclonal | 
		
		
			| Target | 
			env/Env polyprotein | 
		
		
			| Endotoxin level | 
			Please contact the lab for this information. | 
		
		
			| Purity | 
			>95% purity as determined by SDS-PAGE. | 
		
		
			| Purification | 
			Protein A/G, purified from cell culture supernatant. | 
		
		
			| Accession | 
			P03377 | 
		
		
			| Form | 
			Liquid | 
		
		
			| Storage buffer | 
			0.01M PBS,pH7.4. | 
		
		
			| Stability and Storage | 
			Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. | 
		
		
			| Alternate Names | 
			KD-247,CAS:914257-21-9 | 
		
		
			| Background | 
			Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection. | 
		
		
			| Note | 
			For research use only. Not for use in clinical or therapeutic applications. |